Cohort 2 IN-COL patients had lower circulating MAIT cells at baseline compared with IN-NAE.
Prior to therapy, patients who subsequently developed IN-COL had significantly lower circulating MAIT cells at baseline (0.0% of T cells) than those in the IN-NAE group (1.4% p<0.02; Figure 4a-b). This was also the case while on treatment, as IN-COL at the time of colitis (0.0%) had lower counts than those in the IN-NAE group at week 7-10 of TX (0.7%; see Supplementary Table I). Patients with active UC had lower proportions of circulating MAIT cells (0.3%) compared with healthy volunteers (1.0%; p<0.02; Figure 4a). Absence of non-specific background staining for CD161 and CCR6 was demonstrated using isotype control antibodies (see Supplementary Figure 2bi).
There were no differences in the proportion of circulating CD25high CD127low Treg or CD45RA- memory Treg between those with IN-COL and IN-NAE, nor those with UC or healthy volunteers (see Supplementary Table I).